OpenEvidence Valuation Hits 12 Billion Dollars Following 250 Million Dollar Funding Round
OpenEvidence raised 250 million dollars at a 12 billion dollar valuation to scale its medical AI platform which is now used by 40 percent of US physicians.
Insights:
OpenEvidence, an artificial intelligence startup based in the US 
US, announced on January 21, 2026, that it has completed a 250 million dollar Series D funding round. This latest investment values the company at 12 billion dollars, marking a significant milestone as it doubles the 6 billion dollar valuation set in October 2025 when the firm raised approximately 200 million dollars. The funding round was co-led by Thrive Capital and DST Global, reflecting a shift in investor interest toward specialized medical applications with proven clinical utility.
US, announced on January 21, 2026, that it has completed a 250 million dollar Series D funding round. This latest investment values the company at 12 billion dollars, marking a significant milestone as it doubles the 6 billion dollar valuation set in October 2025 when the firm raised approximately 200 million dollars. The funding round was co-led by Thrive Capital and DST Global, reflecting a shift in investor interest toward specialized medical applications with proven clinical utility.The rapid growth in valuation follows a period of significant scaling for the platform, which operates as an AI-powered medical search engine for clinicians. Founded by Daniel Nadler daniel nadler, the company has now raised nearly 700 million dollars in total funding to date. Previous investors contributing to the startup's growth include NVIDIA Corporation and Google Ventures, an investment arm of Alphabet Inc. . The company plans to use the new capital for research and development and to scale its specialized AI architecture.
